IL-1β Controls Proliferation, Apoptosis, and Necroptosis Through the PI3K/AKT/NF-κB Pathway in Leukaemic Lymphoblasts
Authors:
- Zitlal-Lin Victoria-AvilaZVZitlal-Lin Victoria-Avila
- Elba Reyes-MaldonadoERElba Reyes-Maldonado
- María Lililia Dominguez-LopezMDMaría Lililia Dominguez-Lopez
- Jorge Vela OjedaJOJorge Vela Ojeda
- Aranza Lozada RuizARAranza Lozada Ruiz
- Omar Rafael AlemanOAOmar Rafael Aleman
- Ruth Angelica LezamaRLRuth Angelica Lezama
Preprint
- 24 November 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Chronic inflammation and the development of cancer are closely linked, with components that comprise the tumour microenvironment—including proinflammatory cytokines—exerting essential tumourigenic effects. These proinflammatory cytokines include IL-1β, which has been reported to be overexpressed in several cancers and shown to activate several signalling pathways. These pathways may involve kinases such as AKT and Src, and have a broad capacity to activate nuclear factors, including NF-κB, which can regulate the transcription of genes encoding proteins such as cIAP1, Bcl-2, and cyclin D, thereby regulating processes like apoptosis and cell cycle inhibition. The objective of this study was to investigate the role of IL-1β in regulating cell death and proliferation in leukaemic lymphoblasts via the PI3K/AKT/NF-κB pathway. We employed flow cytometry to determine the expression levels and phosphorylation status of various proteins, proliferation was assessed using the CCK-8 kit, and apoptosis was evaluated with the Annexin V kit. Our findings indicate that the signalling pathway activated by IL-1β modulates these cellular processes in leukaemic lymphoblasts. We therefore conclude that IL-1β exerts significant effects on cell death and proliferation in leukaemic lymphoblasts through the PI3K/AKT/NF-κB pathway, with the study’s findings indicating that an inflammatory environment may promote such lymphoblasts to acquire neoplastic characteristics. As such, the proteins involved in the effects evaluated in this work could be considered as potential therapeutic targets for the treatment of Acute Lymphoblastic Leukaemia (ALL).Keywords
All Related Versions
- Version 1, 2025-11-24, Preprints
- Published version: Biomedicines, 14 (1), 41.
This publication has 40 references indexed in Scilit:
- Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitorsScience China Life Sciences, 2022
- Silencing of nuclear factor kappa b 1 gene expression inhibits colony formation, cell migration and invasion via the downregulation of interleukin 1 beta and matrix metallopeptidase 9 in renal cell carcinomaMolecular Biology Reports, 2019
- Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cellsCancer Letters, 2016
- Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillanceCancer Letters, 2013
- Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancerCancer Immunology, Immunotherapy, 2011
- Immunity, Inflammation, and CancerCell, 2010
- An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell TransformationCell, 2009
- IL‐6 induces AGS gastric cancer cell invasion via activation of the c‐Src/RhoA/ROCK signaling pathwayInternational Journal of Cancer, 2007
- Nuclear factor-κB: a friend or a foe in cancer?Biochemical Pharmacology, 2004
- Wortmannin, a specific inhibitor of phosphatidylinositol‐3 kinase, blocks osteoclastic bone resorptionFEBS Letters, 1995